<DOC>
	<DOCNO>NCT02800330</DOCNO>
	<brief_summary>Regorafenib novel oral multi-kinase inhibitor target angiogenic , stromal oncogenic receptor tyrosine kinase . It currently register GIST mCRC . When regorafenib co-administered acid suppressive agent , intra-gastric pH increase , result equilibrium ionized/non-ionized regorafenib may shift less soluble non-ionized form reduces regorafenib bioavailability exposure . Since proton pump inhibitor ( PPIs ) often use regorafenib therapy , drug-drug interaction ( DDI ) confront pharmacists oncologist challenge clinical practice . In study investigator therefore evaluate impact PPI-induced intra-gastric pH elevation regorafenib pharmacokinetics patient GIST mCRC .</brief_summary>
	<brief_title>The Effects Proton Pump Inhibitor Esomeprazole Bioavailability Regorafenib</brief_title>
	<detailed_description>Patients start regorafenib load phase 21 day admit 24 hour hospital pharmacokinetic blood sample day 21 , 49 77 ( ± 1-2 day ) . Patients randomize 2 sequence group ( respectively sequence phase A-B-C phase C-B-A ) . The patient use regorafenib alone ( phase A ) esomeprazole five day ( phase B C ) . To ( completely ) rule pH-dependent DDI regorafenib esomeprazole , phase B study regorafenib give concomitantly five day , phase C regorafenib give 3 hour esomeprazole intake five day ( intragastric pH maximally elevated esomeprazole ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Histological cytological confirm diagnosis mCRC GIST prior treatment specific : 1. mCRCpatients previously treat , consider candidate , available therapy accord common practice . 2 . Irresectable metastatic GIST progress intolerant prior treatment imatinib sunitinib . 3 . ECOG Performance Status ≤ 1 4 . Able willing sign Informed Consent Form 5 . No concurrent ( counter ) use acid reduce drug ( PPIs , H2As and/or antacid ) , esomeprazole 40mg daily study . 6 . No concurrent medication supplement interact esomeprazole regorafenib study period . 7 . Abstain grapefruit , grapefruit juice , herbal dietary supplement , herbal tea study period . 8 . Adequate baseline patient characteristic ( complete blood count , serum biochemistry involve sodium , potassium , creatinin , calculation creatinin clearance ( MDRD ) , AST , ALT , gamma glutamyl transpeptidase , lipase , lactate dehydrogenase , ALP , total bilirubin , albumin , glucose , INR , thyroid function test , PTT APTT within two week prior study ) . 1 . Pregnant lactating patient . 2 . Patients know impaired drug absorption ( e.g . gastrectomy achlorhydria ) . 3 . Known serious illness medical unstable condition could interfere study ; require treatment ( e.g . infection , bleeding , uncontrolled hypertension despite optimal medical management , HIV , hepatitis , organ transplant , kidney , cardiac respiratory disease ) . 4 . Nonhealing wound , nonhealing ulcer , nonhealing bone fracture 5 . Major surgical procedure significant traumatic injury within 28 day start study medication . 6 . Patients evidence history bleed diathesis , irrespective severity 7 . Any hemorrhage bleeding event ≥ CTCAE Grade 3 within 4 week prior start study medication . 8 . Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month start study medication ( except adequately treat catheterrelated venous thrombosis occur one month start study medication ) 9 . Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) 10 . Myocardial infarction le 6 month start study drug . 11 . Uncontrolled cardiac arrhythmia 12 . Symptomatic CNS metastases history psychiatric disorder would prohibit understanding give informed consent . 13 . Interstitial lung disease ongoing sign symptoms time inform consent 14 . Known hypersensitivity study drug , study drug class , excipients formulation . 15 . Known history HIV infection , active hepatitis B C , chronic hepatitis B C require treatment antiviral therapy . 16 . Patients strong CYP3A4 inhibitor inducer eligible study ( see appendix B ) . 17 . The use BCRP Pglycoprotein substrates lead clinically relevant drugdrug interaction concern pharmacokinetics regorafenib . 18 . Unwillingness abstain grapefruit ( juice ) , ( herbal ) dietary supplement , herbal , overthecounter medication ( except paracetamol ibuprofen ) drug know seriously interact esomeprazole regorafenib study period . 19 . Unwillingness abstain acid beverage orange juice acidic beverage ( e.g . CocaCola , 7UP etc . ) morning ( 06.0014.00u AM ) regorafenib treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>